Payden & Rygel Abbott Laboratories Transaction History

Payden & Rygel

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Oct 07, 2024	SELL	$100.73 - $112.44 $11.3 Million - $12.7 Million	-112,590 Closed	0 $0
Q1 2024 Oct 08, 2024	BUY	$109.52 - $120.96 $14.6 Million - $16.1 Million	133,500 New	133,500 $15.2 Million
Q4 2023 Feb 12, 2024	SELL	$90.19 - $110.4 $4.18 Million - $5.12 Million	-46,400 Reduced 22.0%	164,490 $18.1 Million
Q3 2023 Oct 07, 2024	SELL	$95.53 - $114.62 $4.96 Million - $5.95 Million	-51,900 Reduced 31.55%	112,590 $10.9 Million
Q2 2023 Aug 10, 2023	SELL	$100.78 - $112.29 $1.15 Million - $1.28 Million	-11,400 Reduced 5.13%	210,890 $23 Million
Q1 2023 May 10, 2023	BUY	$96.86 - $114.01 $10.7 Million - $12.5 Million	110,060 Added 98.07%	222,290 $22.5 Million
Q4 2022 Feb 13, 2023	SELL	$95.06 - $111.52 $8.49 Million - $9.96 Million	-89,300 Reduced 44.31%	112,230 $12.3 Million
Q3 2022 Nov 10, 2022	BUY	$96.76 - $112.03 $861,164 - $997,067	8,900 Added 4.62%	201,530 $19.5 Million
Q1 2022 Apr 13, 2022	SELL	$114.02 - $139.04 $9.93 Million - $12.1 Million	-87,100 Reduced 31.14%	192,630 $22.8 Million
Q4 2021 Feb 11, 2022	SELL	$115.53 - $141.46 $103,977 - $127,314	-900 Reduced 0.32%	279,730 $39.4 Million
Q2 2021 Aug 06, 2021	BUY	$105.79 - $124.53 $27.7 Million - $32.6 Million	261,900 Added 1398.29%	280,630 $32.5 Million
Q1 2021 May 13, 2021	SELL	$108.84 - $128.23 $17.1 Million - $20.1 Million	-156,700 Reduced 89.32%	18,730 $2.25 Million
Q4 2020 Feb 08, 2021	BUY	$105.0 - $114.42 $18.4 Million - $20.1 Million	175,430 New	175,430 $19.2 Million

3,185

1.3B

8.74M

8.08M

Ticker ABT
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 1,751,219,968
Market Cap $207B
Description
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for t...

Get notified when there are updates to the investment portfolio of Payden & Rygel, based on Form 13F filings with the SEC.

Stay updated on Payden & Rygel with notifications on news.